GUTS
Biotechnology · Healthcare
CFO
Equibles does not estimate personal net worth.
Earlier roles on record: CFO at Fractyl Health, Inc. (GUTS) until December 31, 2025. Fractyl Health, Inc. reported in an 8-K filed January 6, 2026 that Lisa Davidson resigned as Chief Financial Officer, effective December 31, 2025. The same filing states: “The Company appreciates the service of Ms. Davidson and her resignation is not the result of any disagreement with the Board or management on any matter, including the Company's operations, policies or practices.” The proxy statement of Fractyl Health, Inc. reports total compensation of $1,972,272 for Lisa Davidson in fiscal 2024, including a base salary of $445,385. Lisa Davidson has spoken on 7 earnings calls across 1 company, most recently for Fractyl Health, Inc. on November 12, 2025. The companies whose calls Lisa Davidson spoke on are classified in the Healthcare sector.
“Ms. Smith Weber will replace Lisa Davidson, who has resigned from her role as Chief Financial Officer and all other roles she holds with the Company, effective as of December 31, 2025 (the "Separation Date").”
“The Company appreciates the service of Ms. Davidson and her resignation is not the result of any disagreement with the Board or management on any matter, including the Company's operations, policies or practices.”
“Turning now to our financial results for the third quarter of 2025. For the quarter ended September 30th, research and development expenses were $17.5 million compared to $19.0 million for the same period in 2024.”
“In the second quarter of 2025, we continue to invest in the execution of our clinical strategy across both the Revita and Rejuva programs.”
“In the first quarter of 2025, we continued to invest strategically in the clinical and operational progress you just heard about. Research and development expense was $19.4 million, compared to $14.4 million in the first quarter of 2024.”
“In the fourth quarter of 2024, revenue was generated from our commercial pilot in Germany and enabled patients to enroll in the German Real-World Registry study.”
“In the third quarter of 2024, revenue was generated from our commercial pilot in Germany and enable patients to enroll in the German real-world registry study. Turning to operating expenses.”
Start not stated–2025-12-31
GUTS
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Fractyl Health, Inc. (GUTS) | Chief Financial Officer and Treasurer | $445,385 | $1,972,272 |
“The Company appreciates the service of Ms. Davidson and her resignation is not the result of any disagreement with the Board or management on any matter, including the Company's operations, policies or practices.”
Fractyl Health, Inc. (GUTS)